Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Benjamin P. Levy, MD, provides a look at an upcoming Peer Exchange program that will focus on the overall treatment landscape in non–small cell lung cancer and look at recent data in the context of clinical guidelines.
The FDA has granted breakthrough therapy designation to furmonertinib for use as a potential therapeutic option in patients with previously untreated, locally advanced or metastatic nonsquamous non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
Expert oncologist Benjamin P. Levy, MD, shares his excitement for an upcoming program centered on recent data with selpercatinib versus pembrolizumab in patients with non-small cell lung cancer following ESMO 2023.
Martin Dietrich, MD, PhD, provides a look at an upcoming program exploring key data from the phase 3 MARIPOSA-2 study in patients with EGFR-mutated advanced NSCLC.
Stephen V. Liu, MD, discusses the significance of using fam-trastuzumab deruxtecan-nxki in patients with HER2-mutant non–small cell lung cancer and brain metastases according to pooled findings from exploratory analyses of the phase 2 DESTINY-Lung01 and DESTINY-Lung02 trials.